Skip to Content

CIP Newsletter No.135 - August 2011

Funding Announcements

RESEARCH PROJECT GRANT (PARENT R01)(PA-11-260)
Application Receipt Date(s): Multiple dates, see announcement.

URL:  http://grants.nih.gov/grants/guide/pa-files/PA-11-260.html 

2012 NIH DIRECTOR'S PIONEER AWARD PROGRAM (DP1) (RFA-RM-11-004)
Application Receipt Date: October 07, 2011

Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.  To be considered pioneering, the proposed research must reflect ideas substantially different from those being pursued in the investigator’s laboratory or being pursued elsewhere.

URL:   http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-004.html 

ALLIANCE OF GLYCOBIOLOGISTS FOR DETECTION OF CANCER (U01) (NCI)(RFA-CA-11-009)

Letter of Intent Due Date: September 7, 2011

Application Receipt Date: October 07, 2011

The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the “Alliance of Glycobiologists for Detection of Cancer” (http://glycomics.cancer.gov). Through this FOA, the NCI solicits new and competing renewal applications for research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities that have the potential to serve as biomarkers for early cancer detection or risk assessment. 

URL:  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-11-009.html

USING PUBLIC DATA FOR CANCER PREVENTION AND CONTROL:  FROM INNOVATION TO IMPACT

Collaboration of ONC, Health 2.0 and NCI

Phase I submission deadline: August 26, 2011

The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) is announcing the launch of the Using Public Data for Cancer Prevention and Control: From Innovation to Impact Developer Challenge. This Challenge is sponsored by the NCI and is presented as part of the Office of the National Coordinator for Health Information Technology’s Investing in Innovation (i2) program. This contest addresses the NCI DCCPS mission to disseminate information towards the prevention, early detection, diagnosis, treatment, and control of cancer.  Teams are required to address challenges faced by consumers, clinicians, or researchers on the continuum of cancer control. Suggested targets include promoting healthy behaviors (e.g., nutrition, physical activity, smoking cessation), early detection and screening, informed decision-making, and adherence to treatment plans.

URL:  http://bit.ly/nPCOrw

NIH EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAM (PARENT R21) (Multiple ICs, not including NCI, NCRR, NHLBI) (PA-11-261)
Application Receipt Date(s): Multiple dates, see announcement.

The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.

URL:  http://grants.nih.gov/grants/guide/pa-files/PA-11-261.html 

NIH SMALL RESEARCH GRANT PROGRAM (PARENT R03) (Multiple ICs, not including NCI) (PA-11-262)

Application Receipt Dates:  Standard dates apply

The National Institutes of Health (NIH) Investigator-Initiated Small Research Grant (R03) funding opportunity supports small research projects that can be carried out in a short period of time with limited resources.
URL:  http://grants.nih.gov/grants/guide/pa-files/PA-11-262.html

 

INSTRUMENT DEVELOPMENT FOR BIOMEDICAL APPLICATIONS (R21) (NCRR) (RFA-RR-11-005)
Application Receipt Date: October 11, 2011

The primary intent of this FOA is to stimulate the development of instrumentation for biomedical research that will support achievement of biomedical breakthroughs. High-risk applications are encouraged.  IMPORTANT: Proposals primarily focused in the areas of biomedical imaging, sensors, biomaterials, tissue engineering and rehabilitation engineering will be considered nonresponsive.

URL:  http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-11-005.html 

TRANSLATIONAL RESEARCH IN PEDIATRIC AND OBSTETRIC PHARMACOLOGY (NICHD){(R01: PAR-11-246) (R03: PAR-11-247) (R21: PAR-11-248)}
Application Receipt Date(s): October 4, 2011, January 10, 2012, May 15, 2012, September 12, 2012, January 10, 2013, May 15, 2013 

The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and/or in pregnant women and the developing fetus.  Among the topics of interest is identification of markers for the development of new drugs and the application of imaging tools to assess drug effects, toxicity, and safety, as well as clinical outcomes. 

URL for R01:  http://grants.nih.gov/grants/guide/pa-files/PAR-11-246.html 

URL for R03:  http://grants.nih.gov/grants/guide/pa-files/PAR-11-247.html 

URL for R21:  http://grants.nih.gov/grants/guide/pa-files/PAR-11-248.html 


 INSTITUTIONAL RESEARCH AND ACADEMIC CAREER DEVELOPMENT AWARDS (IRACDA) (K12) (NIGMS) (PAR-11-255)
Application Receipt Date(s): September 22, 2011

The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to developa diverse group of highly trained biomedical and behavioral scientists to address the Nation’s biomedical, behavioral, and clinical research needs. The program promotes consortia between research-intensive institutions (RII) and partner institutions that have a historical mission and a demonstrated commitment to the training, encouragement and assistance to students from groups underrepresented in the biomedical and behavioral research enterprise of the nation.

URL:  http://grants.nih.gov/grants/guide/pa-files/PAR-11-255.html 


2012 NIDA TRANSLATIONAL AVANT-GARDE AWARD FOR MEDICATION DEVELOPMENT FOR  THE TREATMENT OF  SUBSTANCE-USE DISORDERS (DP1) (RFA-DA-12-010)
Application Receipt Date: February 21, 2012

The purpose of this funding opportunity is to advance the development of safe and efficacious medications (small molecules or biologics) for the treatment of Substance-Use Disorders (SUDs). Small molecules are organic compounds with drug-like properties, whereas biologics may include, for example, vaccines or recombinant therapeutic proteins.  See the announcement for appropriate and inappropriate topics.  See PAR-11-69 below for Pre-Application.

URL:  http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html 

PRE-APPLICATION FOR THE 2012 NIDA TRANSLATIONAL AVANT-GARDE AWARD FOR MEDICATION DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE-USE DISORDERS (X02) (PAR-11-269)
Application Receipt Date: October 20, 2011

The 2012 Translational Avant-Garde Award competition will proceed in two phases. The X02 pre-application is the first phase.  X02 pre-applications will be reviewed by external reviewers to identify the most outstanding applications. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full DP1 grant applications under RFA-DA-12-010. All awards will be made under RFA-DA-12-010.  No awards will be made under this announcement.

URL for Pre-Application: http://grants.nih.gov/grants/guide/pa-files/PAR-11-269.html

Notices

Imaging Boot Camp for Cancer Researchers – article in NCI Cancer Bulletin: http://www.cancer.gov/ncicancerbulletin/062811/page5

NEW FDA CGMP GUIDANCE FOR SMALL BUSINESSES AVAILABLE
The Food and Drug Administration (FDA) has announced the availability of a guidance for small business entities entitled, "PET Drugs -- Current Good Manufacturing Practice(CGMP); Small Entity Compliance Guide." The guideline is intended to help small businesses better understand FDA’s thinking on compliance with the positron emission tomography drugs (PET) CGMP regulations, including appropriate resources, procedures, and documentation for PET drug production facilities.      

URL:  http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM266640.pdf

NIH, AHRQ, CDC, FDA AND NIOSH TO RELEASE UPDATED ELECTRONIC APPLICATION FORMS – ADOBE-FORMS-B2  (NOT-OD-11-096)
The ADOBE-FORMS-B2 packages will be used with new funding opportunity announcements (FOAs) posted on/after July 22, 2011.

URL:  http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-096.html 

MANDATING USE OF THE COMMONS TO SUBMIT NO-COST EXTENSION NOTIFICATIONS (NOT-OD-11-098)

Effective October 1, 2011, NIH is requiring  grantees to use the No-Cost Extension feature in the eRA Commons to notify NIH when they exercise their one-time authority to extend, without additional funds, the final budget period of a grant.  NIH will no longer accept these notifications via other communication channels. 
URL:  http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-098.html

REQUEST FOR INFORMATION (RFI): PROPOSED FUNDING PRIORITIES FOR NEUROSCIENCE RESEARCH, RESOURCES AND TOOLS (NIH NEUROSCIENCE BLUEPRINT) (Multiple ICs)  (NOT-MH-11-016)

Response date: September 9, 2011

The NIH Blueprint is considering how best to invest its funds in future fiscal years. For FY2012 and FY2013, it is anticipated that limited funding will be available each year (no more than $4 million) while FY2014 may provide greater flexibility as several NIH Blueprint projects come to an end. Keeping in mind that the NIH Blueprint is interested in ideas that are broadly relevant across diseases and participating ICs, responses are requested to the questions below:

  • Identify areas of neuroscience research that could be accelerated by the development of specific research resources or tools.
  • What are the major opportunities for, and impediments to, advancing neuroscience research?
  • What are the 2-3 highest priority tools or resources needed to capitalize on the scientific opportunities and overcome obstacles to progress in neuroscience research?
  • Describe how NIH Blueprint might best facilitate the development of these tools/resources.

URL:  http://grants.nih.gov/grants/guide/notice-files/NOT-MH-11-016.html 


NIH OFFERS SBIR NICHE ASSESSMENT PROGRAM TO PHASE I AWARDEES  (NOT-OD-11-094)
NIH announces the availability of a Niche Assessment Program for its SBIR Phase I awardees funded in fiscal years (FY) 2011 and 2012. All active NIH SBIR Phase I awardees as well as those small businesses selected to receive a Phase I award in the first three months of the upcoming fiscal year will be eligible to participate (STTR awards are not eligible).

URL:  http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-094.html 

NIH OFFERS COMMERCIALIZATION ASSISTANCE PROGRAM TO SBIR PHASE II AWARDEES; APPLICATIONS DUE SEPTEMBER 1, 2011 (NOT-OD-11-102)
The purpose of this Notice is to announce the availability of a Commercialization Assistance Program (CAP) for NIH SBIR Phase II awardees. Now in its eighth year, this program is designed to help NIH SBIR Phase II awardees transition their SBIR-developed products into the marketplace.

URL:  http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-102.html

CIP Announcements
GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE 
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at micad@ncbi.nlm.nih.gov. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
URL: http://micad.nih.gov
URL: http://bookshelf.ncbi.nlm.nih.gov/books/bookres.fcgi/micad/infoguest.html
) 

Meetings

Cancer Detection and Diagnostics Technologies for Global Health 
August 22-23, 2011, Natcher Center, NIH Campus, Bethesda, MD

URL:  http://web.ncifcrf.gov/events/cancerdetection/default.asp

2011 International Symposium on Radiopharmaceutical Sciences

August 28 - September 2, 2011, Amsterdam, the Netherlands

URL:  http://www.isrs2011.org/

2011 World Molecular Imaging Congress

September 7-10, 2011, San Diego Convention Center, San Diego, CA

URL:  http://www.wmicmeeting.org/home/

 

10th International Tissue Elasticity Conference
October 12th - 15th, 2011, Sheraton Arlington Hotel, Arlington, TX

URL: http://www.elasticityconference.org/

 

IEEE Nuclear Science Symposium and Medical Imaging Conference 
October 23rd - 29th, 2011, Valencia, Spain

URL: http://www.nss-mic.org/

8th Annual Memphis BioImaging Symposium

November 3-4, 2011, Fogelman Executive Conference Center, Memphis, TN

URL:  http://www.membis.org/

RSNA 2011
November 27 - December 2, 2011, McCormick Place, Chicago, IL
URL:  http://www.rsna.org/

SPIE Medical Imaging Conference
February 4-9, 2012, Town and Country Resort and Convention Center, San Diego, VA
URL: http://spie.org/x12166.xml

 

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail   (bc129b@nih.gov).
Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531Fax: 301 480 3507